Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2022）
摘要
Drug desensitization in 12 or 16 steps allows tolerable administration of brentuximab vedotin after moderate to severe anaphylaxis. The favorable response to treatment of these patients may indicate that desensitization is a viable strategy for patients with relapsed or refractory HL.
更多查看译文
关键词
Anaphylaxis,Hodgkińs lymphoma,brentuximab vedotin,desensitization
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要